Raymond James Financial Inc. Acquires New Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Raymond James Financial Inc. bought a new position in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 131,505 shares of the company's stock, valued at approximately $746,000. Raymond James Financial Inc. owned approximately 0.24% of Voyager Therapeutics as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of VYGR. Rhumbline Advisers lifted its stake in shares of Voyager Therapeutics by 3.4% in the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock valued at $405,000 after buying an additional 2,354 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of Voyager Therapeutics by 5.3% in the 4th quarter. Empowered Funds LLC now owns 47,206 shares of the company's stock worth $268,000 after acquiring an additional 2,397 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Voyager Therapeutics by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company's stock valued at $804,000 after purchasing an additional 3,473 shares during the last quarter. Geode Capital Management LLC boosted its stake in Voyager Therapeutics by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company's stock valued at $6,316,000 after purchasing an additional 6,740 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in Voyager Therapeutics by 23.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company's stock worth $223,000 after purchasing an additional 7,573 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on VYGR. Cantor Fitzgerald restated an "overweight" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group cut their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, March 13th. Wedbush reiterated an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the stock an "overweight" rating in a report on Wednesday, March 12th. Finally, HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $13.97.

Insiders Place Their Bets

In related news, CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the sale, the chief executive officer now owns 430,931 shares of the company's stock, valued at approximately $1,478,093.33. This represents a 2.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 15,163 shares of company stock worth $59,158 over the last 90 days. Corporate insiders own 4.53% of the company's stock.

Voyager Therapeutics Trading Down 3.9 %

Shares of VYGR stock traded down $0.12 on Thursday, hitting $2.99. 288,996 shares of the stock were exchanged, compared to its average volume of 461,908. Voyager Therapeutics, Inc. has a one year low of $2.75 and a one year high of $9.55. The firm's 50 day moving average is $3.99 and its two-hundred day moving average is $5.41. The firm has a market capitalization of $165.07 million, a PE ratio of 4.21 and a beta of 1.02.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The business had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period last year, the firm earned $1.25 EPS. On average, sell-side analysts expect that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.